Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genelux Corp. ( (GNLX) ) has issued an announcement.
On March 19, 2026, Genelux Corporation entered into a Sales Agreement with TD Securities (USA) LLC, allowing the company to offer and sell up to $100 million of its common stock from time to time through at-the-market offerings and other negotiated transactions. The shares will be issued under an existing shelf registration statement, and Genelux may suspend or terminate sales at its discretion while TD Cowen acts as sales agent or principal.
Genelux plans to use the net proceeds for general corporate purposes, including research and development, clinical trial expenses, capital expenditures and working capital, potentially extending its financial runway for oncology programs. TD Cowen will receive up to 3.0% of gross proceeds as compensation and reimbursement of certain expenses, under customary terms that include representations, covenants, indemnities and mutual termination rights, shaping a flexible capital-raising framework for the company and its stakeholders.
The most recent analyst rating on (GNLX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Genelux Corp. stock, see the GNLX Stock Forecast page.
Spark’s Take on GNLX Stock
According to Spark, TipRanks’ AI Analyst, GNLX is a Neutral.
The score is held down primarily by negligible revenue with large ongoing losses and heavy cash burn, alongside bearish technicals with the stock trading below key moving averages. Positive corporate developments (early trial signals, leadership hire, and added financing capacity) help, but are not enough to outweigh current financial weakness and dilution risk.
To see Spark’s full report on GNLX stock, click here.
More about Genelux Corp.
Genelux Corporation is a biotechnology company that focuses on the development of oncology therapies, with an emphasis on research and clinical trials to advance its pipeline of cancer treatments. The company operates in the life sciences sector and accesses the capital markets via its listing on The Nasdaq Capital Market to fund development and corporate activities.
Average Trading Volume: 232,982
Technical Sentiment Signal: Sell
Current Market Cap: $115.8M
Learn more about GNLX stock on TipRanks’ Stock Analysis page.